GlassScriptPhysician profile
Thandar A Win
NPI 1629308630
$4,941.03
in general payments reported to CMS, 2019-2025
17 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $104 · 2021: $426 · 2022: $767 · 2023: $845 · 2024: $1,020 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,306.82 |
| Education | $198.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,217.73 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,019.75 | 2021-2025 | Vraylar |
| Alkermes, INC. | $634.15 | 2019-2024 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $478.55 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $335.01 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $284.50 | 2022-2025 | Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.74 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $248.88 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $184.57 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $80.08 | 2025 | Cobenfy |
| Tris Pharma INC | $54.62 | 2025 | Dyanavel Xr |
| Corium, LLC | $41.59 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $32.62 | 2023-2024 | Trintellix |
| Indivior INC. | $23.31 | 2024 | Sublocade |
| Jazz Pharmaceuticals INC. | $20.46 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17.00 | 2020 | |
| Eisai INC. | $15.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thandar Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.